Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.72 |
| ▸ | NPC1 | O15118 | 8/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.72 |
| ▸ | RELA | Q04206 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31612285 | 0.88 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL3635519 | 0.86 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL6569873 | 0.85 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL2665808 | 0.78 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL13210626 | 0.77 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL10144689 | 0.77 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL18719840 | 0.77 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL15695713 | 0.76 | ALDH1A1 (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL28361969 | 0.75 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL29650441 | 0.75 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2ALDH1A1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | DEPARTMENT OF VETERANS AFFAIRS | 2009-02-12 | — | — | US | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM3 | RAB9A 3119/4885NPC1 2371/4885SMN1; SMN2 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.